Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer

Background Multi-gene prognostic signatures derived from primary tumor biopsies can guide clinicians in designing an appropriate course of treatment. Identifying genes and pathways most essential to a signature performance may facilitate clinical application, provide insights into cancer progression, and uncover potentially new therapeutic targets. We previously developed a 17-gene prognostic signature (HTICS) for HER2+:ERα- breast cancer patients, using genes that are differentially expressed in tumor initiating cells (TICs) versus non-TICs from MMTV-Her2/neu mammary tumors. Here we probed the pathways and genes that underlie the prognostic power of HTICS. Methods We used Leave-One Out, Data Combination Test, Gene Set Enrichment Analysis (GSEA), Correlation and Substitution analyses together with Receiver Operating Characteristic (ROC) and Kaplan-Meier survival analysis to identify critical biological pathways within HTICS. Publically available cohorts with gene expression and clinical outcome were used to assess prognosis. NanoString technology was used to detect gene expression in formalin-fixed paraffin embedded (FFPE) tissues. Results We show that three major biological pathways: cell proliferation, immune response, and cell migration, drive the prognostic power of HTICS, which is further tuned by Homeostatic and Glycan metabolic signalling. A 6-gene minimal Core that retained a significant prognostic power, albeit less than HTICS, also comprised the proliferation/immune/migration pathways. Finally, we developed NanoString probes that could detect expression of HTICS genes and their substitutions in FFPE samples. Conclusion Our results demonstrate that the prognostic power of a signature is driven by the biological processes it monitors, identify cell proliferation, immune response and cell migration as critical pathways for HER2+:ERα- cancer progression, and defines substitutes and Core genes that should facilitate clinical application of HTICS.

[1]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[2]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[3]  J. Moffat,et al.  shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. , 2014, Cancer research.

[4]  M. Hallett,et al.  The prognostic ease and difficulty of invasive breast carcinoma. , 2014, Cell reports.

[5]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[6]  Gary D Bader,et al.  Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer , 2012, Proceedings of the National Academy of Sciences.

[7]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[8]  F. Esteva,et al.  Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.

[9]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Bragado,et al.  Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.

[11]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[12]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[14]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[15]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[16]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[18]  T. Deng,et al.  Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. , 2007, Cancer research.

[19]  C. Arteaga,et al.  New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available , 2011, Clinical Cancer Research.

[20]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[21]  Gary D Bader,et al.  Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K , 2014, EMBO molecular medicine.

[22]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[23]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[24]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[25]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[26]  A. Vincent-Salomon,et al.  Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay , 2016, PloS one.

[27]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Strasser-Weippl,et al.  Prevention Strategies with Aromatase Inhibitors , 2004, Clinical Cancer Research.

[29]  E. Perez,et al.  Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[31]  L. Gianni,et al.  The immune system and response to HER2-targeted treatment in breast cancer. , 2014, The Lancet. Oncology.

[32]  Joe Gray,et al.  Genomics: The breast cancer landscape , 2012, Nature.

[33]  Liliana Florea,et al.  Transcriptomic landscape of breast cancers through mRNA sequencing , 2012, Scientific Reports.

[34]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[35]  J. Hassell,et al.  A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer , 2012, Scientific Reports.

[36]  S. Egan,et al.  A Tumor initiating cell-enriched prognostic signature for HER2+:ERα− breast cancer; rationale, new features, controversies and future directions , 2013, Oncotarget.

[37]  F. Bertucci,et al.  Disulfiram (DSF) acts as a copper ionophore to induce copper‐dependent oxidative stress and mediate anti‐tumor efficacy in inflammatory breast cancer , 2015, Molecular oncology.

[38]  M. Devocelle,et al.  A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells , 2005, British Journal of Cancer.

[39]  Yibin Kang,et al.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients. , 2013, Cancer cell.

[40]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[41]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[42]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[43]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[44]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.